ESElaine Soon

Elaine Soon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elaine Soon has a total of 182 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Interrogating the Glycolytic Axis in Pulmonary Hypertension Models: Potential Targets for Therapy

    by Rachel L. Sutcliffe, Iona Cuthbertson, Stephen Moore, Mark Southwood, Laura de La Bastida Casero, Benjamin Dunmore, Stefan J. Marciniak, Paul Upton, Nicholas Morrell, Paola Caruso, et al.

    Pulmonary artery ECs from PAH patients display reduced oxidative phosphorylation and increased anabolic and pro‐proliferative effects (“Warburg phenomenon”). TEPP‐46 (allosteric stabilizer of tetrameric PKM2) has beneficial effects in wild‐type and BMPR2‐mutation bearing BOECs, ameliorates the increased right ventricular systolic pressures, and improves survival in Sugen‐hypoxia‐exposed rats. Antagonizing the Warburg effect may offer novel therapeutic options for PAH.

  • Open Access

    Interleukin-6 is critical in the development of pulmonary vascular disease in Gcn2-deficient mice.

    by Max Schwiening, Qingyue Gao, Mark Southwood, Alexi Crosby, Stephen Moore, Jose A Valer, Niki Veale, Benjamin J Dunmore, Paul D Upton, A A Roger Thompson, et al.

    Biallelic mutations in EIF2AK4, encoding Eukaryotic Translation Initiation Factor 2α kinase 4 or General Control Nonderepressible 2 (GCN2), cause pulmonary veno-occlusive disease (PVOD), a fatal form of pulmonary hypertension. The mechanisms linking GCN2 deficiency with pulmonary vascular pathology are poorly understood. To investigate this, we developed two mouse models: genetic ablation of Gcn2, to mirror GCN2-mutation positive PVOD, and a pharmacological model using mitomycin C, a drug which can cause PVOD as an idiosyncratic drug reaction. Both models were phenotyped, and lungs from wild-type and Gcn2-deficient mice were analyzed using single-cell RNA sequencing. We show that homozygous loss of Gcn2 is sufficient to induce mild pulmonary hypertension in mice. Single-cell transcriptomic profiling identified adventitial fibroblasts as the cell population exhibiting the most Gcn2-dependent transcriptional changes. Pathway analysis revealed upregulation of inflammatory signaling in Gcn2-/- adventitial fibroblasts. Consistent with this, we demonstrate a proinflammatory phenotype in Gcn2-/- mouse fibroblasts and in Gcn2-/- mice. Using a mitomycin C-induced murine model, genetic deletion of interleukin-6 (Il6) rescued the pulmonary vascular phenotype. Furthermore, chronic lipopolysaccharide exposure exaggerated pulmonary hypertension in Gcn2-/- mice, and Il6 ablation rescued both baseline and lipopolysaccharide-exacerbated disease. Pharmacological inhibition or genetic ablation of the Integrated Stress Response, which can be driven by GCN2-activation, phenocopies Gcn2 deficiency. Therefore, we establish a regulatory effect of an intact GCN2-Integrated Stress Response on IL-6 signaling. Together, we show that interleukin-6 is a critical mediator of both Gcn2 deficiency-associated and mitomycin C-triggered pulmonary vascular disease in mice and highlight IL-6-dependent pathways as potential therapeutic targets.


  • Open Access

    Tracking the evolution of biomarker efficacy in SARS-CoV-2: a global meta-analyses series

    by Me Rahman Shuvo, Max Schwiening, Nikos Avramidis, Felipe Soares, Oliver Feng, Susana Abreu, Niki Veale, William Thomas, A. A. Roger Thompson, Richard J. Samworth, et al.

    Sophisticated prognostic scores have been proposed for SARS-CoV-2 but do not always perform consistently. We performed this systematic review to discover why and to investigate the impact of vaccination and viral variants. We searched the PubMed database for the keywords ‘SARS-CoV-2’ or ‘Covid19’ with ‘biomarker’ and ‘mortality’ for the baseline tranche (01/12/2019–30/06/2021) and either ‘SARS-CoV-2’ or ‘Covid19’ with ‘biomarker’ and either ‘vaccination’ or ‘variant’ from 01/12/2020 to 31/10/2023. To aggregate the data, the meta library in R was used, and a random effects model fitted to obtain pooled AUCs and 95% confidence intervals. We screened 4,688 potential source manuscripts and included 144 in the final analyses. Biomarker effectiveness varies significantly by geographical region. Admission CRP levels were a good prognostic marker for mortality due to wild-type virus in Asian countries, with a pooled area under curve (AUC) of 0.83 (95%CI 0.80–0.85), but only an average predictor of mortality in Europe/Northern America, with a pooled AUC of 0.67 (95%CI 0.63–0.71, P < 0.0001). The same pattern applies to D-dimer and IL-6. Notably, urea and troponin had pooled AUCs ≥ 0.78 regardless of location, implying that end-organ damage at presentation was a key prognostic factor in wild-type SARS-CoV-2 infection. CRP, D-dimer, and IL-6 have generally declined in effectiveness in the vaccinated and variant cohorts. We note a significant lag from the pandemic advent to data availability and that the type of data varied considerably between studies. Biomarkers and prognostic scores should be tailored to populations. It is imperative that the infrastructure for collecting clinical data should be put in place ahead of a future pandemic so that data harvesting, collation and analysis can occur in a robust and timely manner to aid clinical decision making. This study was registered with PROSPERO (CRD42022366893). The online version contains supplementary material available at 10.1186/s12931-026-03656-9.

  • Open Access

    Interrogation of the glycolytic axis in pulmonary arterial hypertension models and how modifying these can lead to potential therapeutic options

    by Rachel Sutcliffe, Iona Cuthbertson, Stephen Moore, Mark Southwood, Benjamin Dunmore, Paul Upton, Nicholas Morrell, Paola Caruso, Elaine Soon

    Introduction: Pulmonary arterial hypertension (PAH) describes diseases characterized by increased pulmonary vessel pressures that lead to right ventricular failure and death if left untreated. Dysregulated metabolic function has been reported in endothelial cells from PAH patients. Healthy endothelial cells can rapidly shift from quiescence to proliferative and apoptotic states, partly due to a greater utilization of glycolysis for ATP production, rather than the slower oxidative phosphorylation more commonly relied on by other cell types. However, in PAH patients, pulmonary artery endothelial cells demonstrate an even greater shift towards glycolytic ATP production. This phenomenon, which was first described in cancer as the ‘Warburg effect’, is an adaptation for optimizing both energy production and biosynthetic processes for maximum proliferative potential. Hypothesis and Methods: We hypothesize that targeting the PKM2 axis in endothelial cells may shift the balance to favor oxidative phosphorylation, in effect ‘reversing’ the Warburg effect; and that this would have beneficial effects in cell and rodent models of PAH. To this end we have tested TEPP-46, an allosteric PKM2 activator that stabilizes the tetrameric form, blocking its translocation into the nucleus and increasing canonical enzymatic activity, in blood outgrowth endothelial cells (BOECs) and in a rat Sugen-hypoxia model. Results: TEPP-46 treatment reduced levels of nuclear PKM2 (the homodimer form which promotes anabolic effects and proliferation). Cytoplasmic levels of PKM2 and levels of PKM1 were unaffected. Exposure to TEPP-46 lowered levels of polypyrimidine tract-binding protein 1 (PTPB1), which controls alternative splicing of the PKM gene to promote PKM2 expression; and reduced LDHA, which converts pyruvate to lactate, preventing its utilization for oxidative phosphorylation. In the Sugen-hypoxia rat model, administration of TEPP-46 significantly ameliorated the elevated right ventricular systolic pressures, reduced the loss of body weight and increased survival. The increased muscularization of the smaller blood arteries and arterioles in the lungs of rats due to Sugen-hypoxia were also improved by concurrent administration of TEPP-46. Conclusion: We have shown that TEPP-46 treatment reduces nuclear PKM2 and represses PKM2-driven gene expression, with the functional effect of ameliorating the Sugen-hypoxia phenotype. This suggests that antagonizing the Warburg effect may offer a novel therapeutic avenue for PAH.

  • Open Access

    Interleukin-6 is critical in the development of gcn2- mutation associated pulmonary vascular disease in mice

    by Max Schwiening, Qingyue Gao, Mark Southwood, Alexi Crosby, Stephen Moore, Jose Antonio Valer, Niki Veale, Benjamin J. Dunmore, Paul D. Upton, Roger Thompson, et al.

    Biallelic mutations in eukaryotic translation initiation factor 2 α kinase 4, EIF2AK4 (which encodes general control nonderepressible 2, GCN2) underpin heritable forms of pulmonary veno-occlusive disease (PVOD), a rare and fatal form of pulmonary hypertension. The mechanisms linking these are mostly uncharacterised. We demonstrate for the first time that homozygous loss of gcn2 is sufficient to cause mild pulmonary hypertension in mice. Single-cell transcriptomics of mouse lungs identified adventitial fibroblasts as having the greatest GCN2-dependent transcriptional differences, implicating them as key players in this model of PVOD. The most significantly upregulated pathways in gcn2 -/- adventitial fibroblasts were inflammatory. Therefore, we went on to demonstrate a pro-inflammatory phenotype in gcn2 -/- mouse embryonic fibroblasts and gcn2 -/- mice. In a novel murine model of pulmonary hypertension induced by exposure to mitomycin C, deletion of interleukin-6 rescued the pulmonary vascular phenotype. When chronically exposed to lipopolysaccharide, the pulmonary hypertensive phenotype of gcn2 -/- mice is exaggerated. Genetic ablation of interleukin-6 completely rescues both the baseline and LPS-exaggerated pulmonary hypertensive phenotype. Targeting Il6 -dependent pathways may be useful in treating this deadly disease.

  • Open Access

    Cigarette smoke induces PPP1R15A via oxidative stress to modulate inflammatory cytokine production by bronchial epithelial cells

    by Gimano D. Amatngalim, Annemarie van Schadewijk, Anne M. van der Does, Maria C. Zarcone, Elke Malzer, Jayson Bradley, Jose A. Valer, Elaine Soon, Elizabeth Timmins, Mark Southwood, et al.

    Cigarette smoke is the principal cause of chronic obstructive pulmonary disease (COPD) in Western societies. It induces pulmonary inflammation and activates multiple stress signalling pathways in bronchial epithelial cells, including the integrated stress response (ISR). The ISR is triggered by phosphorylation of the translation initiation factor eIF2α in response to a variety of insults and is functionally antagonised by the eIF2α phosphatase subunit PPP1R15A. Deletion of PPP1R15A exaggerates the ISR and, in many models, protects against cellular stress. However, loss of PPP1R15A was also shown to exaggerate pulmonary fibrosis in bleomycin-challenged mice. We therefore wished to understand the role of PPP1R15A in the pulmonary response to cigarette smoke, which can cause both COPD and pulmonary fibrosis. Whole cigarette smoke rapidly activated the ISR in differentiated mucociliary human primary bronchial epithelial cells, with those from COPD patients exhibiting higher levels of ISR. Acute exposure to cigarette smoke condensate induced a pro-inflammatory cytokine response accompanied by PPP1R15A expression. In this model, PPP1R15A induction was independent of eIF2α phosphorylation but was suppressed by antioxidants, suggesting a response to oxidative stress. In vivo studies in mice revealed that PPP1R15A deficiency enhanced the secretion of proinflammatory cytokines in mice, suggesting a regulatory role for PPP1R15A in modulating the inflammatory response to smoke. Taken together, these data suggest that PPP1R15A is induced by cigarette smoke by an ISR-independent oxidative stress mechanism and ameliorates the pro-inflammatory cytokine response to cigarette smoke.

  • Unpicking the Effects of General Control Non-depressible 2 (GCN2) Deficiency in Pulmonary Veno-Occlusive Disease

    by M. Schwiening, S. Moore, R. Nibhani, A. Crosby, M. Southwood, B. Dunmore, H. Turton, R. Thompson, N.W. Morrell, S.J. Marciniak, et al.

  • Open Access

    Mapping of biomarker efficacy in SARS-CoV-2: tracking the impact of viral mutations and vaccinations

    by Me Rahman Shuvo, Max Schwiening, Nikos Avramidis, Felipe Soares, Oliver Feng, Susana Abreu, Niki Veale, Q Gao, William Thomas, Aa Roger Thompson, et al.

    Objectives Sophisticated scores have been proposed for prognostication of mortality due to SARS-CoV-2 but perform inconsistently. We conducted these meta-analyses to uncover why and to pragmatically seek a single dependable biomarker for mortality. Design We searched the PubMed database for the keywords ‘SARS-CoV-2’ with ‘biomarker name’ and ‘mortality’. All studies published from 01st December 2019 to 30th June 2021 were surveyed. To aggregate the data, the meta library in R was used to report overall mean values and 95% confidence intervals. We fitted a random effects model to obtain pooled AUCs and associated 95% confidence intervals for the European/North American, Asian, and overall datasets. Setting and Participants Data was collected from 131 studies on SARS-CoV-2 PCR-positive general hospital adult admissions (n=76,169 patients in total). Main Outcome Measures We planned a comparison of pooled area under curves (AUCs) from Receiver Operator Characteristic curves plotted for admission D-dimer, CRP, urea, troponin and interleukin-6 levels. Main Results Biomarker effectiveness varies significantly in different regions of the world. Admission CRP levels are a good prognostic marker for mortality due to SARS-CoV-2 in Asian countries, with a pooled area under curve (AUC) of 0.83 (95% CI 0.80-0.85), but only an average predictor of mortality in Europe/North America, with a pooled AUC of 0.67 (95% CI 0.63-0.71, PConclusions Biomarker effectiveness for prognosticating SARS-CoV-2 mortality varies significantly by geographical location. We propose that biomarkers and by extension prognostic scores need to be tailored for specific populations. This also implies that validation of commonly used prognostic scores for other conditions should occur before they are used in different populations. Section 1: What is already known on this topic Biomarkers such as CRP, D-dimer, and interleukin-6 have been proven to have prognostic value in SARS-CoV-2. However prognostic scores using these as building blocks perform unevenly in different locations. Section 2: What this study adds Commonly used biomarkers for SARS-CoV-2 have different efficacy in different parts of the world. For example, admission CRP and interleukin-6 levels are good prognostic markers for mortality in Asian countries but only average in Europe and North America. Prognostic markers and scores cannot be ‘transplanted’ from one region to another. This has implications not just for SARS-CoV-2 but also for scores in other conditions.

  • Open Access

    Different Cytokine Patterns in BMPR2-Mutation-Positive Patients and Patients With Pulmonary Arterial Hypertension Without Mutations and Their Influence on Survival

    by Max Schwiening, Emilia M. Swietlik, Divya Pandya, Keith Burling, Peter Barker, Oliver Y. Feng, Carmen M. Treacy, Susana Abreu, S. John Wort, Joanna Pepke-Zaba, et al.